Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
NCT05444465
Recruiting
The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Harbin Clinic, Rome, Georgia +19 locations
Conditions: Rotator Cuff Injuries
Register for Updates
The Poor Responders Study
NCT05404061
Recruiting
Obesity and type 2 diabetes are major causes of illness and premature death worldwide and their incidence is increasing rapidly. Bariatric surgery is considered as the "gold-standard" surgical treatment for both conditions. However, not all patients do equally well after surgery and indeed the weight loss experienced by patients undergoing bariatric surgery can vary. As such when patients are seen after bariatric surgery in clinic they fall in one of the following two categories: 1. Good respo... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2025
Locations: Imperial College London, London, Not set
Conditions: Bariatric Surgery Candidate, Obesity, Morbid, Diabetes Mellitus, Type 2
Register for Updates
A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE)
NCT06333483
Recruiting
This is a Phase I study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Hospital Universitari Vall Hebrón, Barcelona, Not set +2 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Loma Linda University Health, Loma Linda, California +25 locations
Conditions: Inappropriate Sinus Tachycardia
Register for Updates
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865
Recruiting
The goal of this observational study is to collect mid-term post-market clinical follow-up data of GORE® TAG® Thoracic Branch Endoprosthesis used according to the standard medical practice in patients presenting with vascular disease. This registry aims to answer questions related to the efficacy and safety of GORE® TAG® Thoracic Branch Endoprosthesis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Medizinische Universität Wien, Wien, Not set +19 locations
Conditions: Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Transection Aorta
Register for Updates
VItamin C in Thermal injuRY: The VICToRY Trial
NCT04138394
Recruiting
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Arizona Burn Center Valleywise Health, Phoenix, Arizona +33 locations
Conditions: Shock, Thermal Burn
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Arizona Digestive Health, Sun City, Arizona +122 locations
Conditions: Ulcerative Colitis
Register for Updates
ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG
NCT06959719
Recruiting
This is a randomised controlled trial evaluating whether controlled air introduction into pleural space (air entrainment) during pleural effusion drainage reduces pain, improves patient satisfaction, and facilitates more effective drainage in patients with non-expandable lung (NEL). NEL lung is a common complication in patients with malignant or chronic pleural effusions, where the lung fails to fully re-expand after fluid removal due to pleural disease or fibrosis. In these patients, drainage... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2025
Locations: Addenbrooke's Hospital, Cambridge, Cambridgeshire
Conditions: Non-expandable Lung, Trapped Lung, Pleural Effusion, Malignant Pleural Effusions (Mpe)
Register for Updates
Chyme Reinfusion for Type 2 Intestinal Failure
NCT04577456
Recruiting
This project aims to introduce and evaluate a novel assistive prosthetic system that helps prevent and treat nutrient and fluid loss from enterocutaneous fistulas. The device system functions simply to return the output from a fistula back into the distal limb of the intestine.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/04/2025
Locations: Shands Hospital, Gainesville, Florida +9 locations
Conditions: Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma
Register for Updates
The Effect of Pistachio-Rich Breakfast Meals on Cognitive Function in Healthy Older Adults
NCT06900452
Recruiting
This study aims to investigate the effect of a breakfast meal containing varying serving sizes (doses) of pistachio nuts on cognitive function throughout the course of the day in healthy ageing adults aged 65-80.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/02/2025
Locations: Nutrition, Cognition & Health Lab, School of Psychology and Clinical Language Sciences, University of Reading, Reading, Berkshire
Conditions: Cognition
Register for Updates
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
NCT06957808
Recruiting
Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in 6-12 months and continue to experience psychotic symptoms. Therefore, there is a strong unmet need for new evidence-based treatments to target the neurobiology underlyi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2025
Locations: South London and Maudsley NHS Foundation Trust, London, Greater London +2 locations
Conditions: Schizophrenia Disorders
Register for Updates
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820
Recruiting
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards. The stand... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
05/02/2025
Locations: University of California Irvine, Irvine, California +50 locations
Conditions: Pompe Disease (Late-onset)
Register for Updates